

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-22 are cancelled.

23. (Currently Amended) A method of activating a central nervous system receptor in a subject in need of an effect mediated in the central nervous system, the method comprising bringing said receptor into contact with peripherally administering to the subject an amphiphilic drug-oligomer conjugate comprising a therapeutic compound conjugated to an oligomer, wherein the oligomer comprises a lipophilic moiety coupled with a hydrophilic moiety, and wherein the conjugate traverses the blood-brain barrier of the subject to come into contact with and activate the receptor and thereby produce the effect.
24. (Currently Amended) The method of claim 1 ~~23~~, ~~further characterized in that said~~ wherein the conjugate exhibits activity in the central nervous system ~~the~~ without cleavage of the therapeutic compound from the oligomer.
25. (Currently Amended) The method of claim 1 ~~23~~, wherein the receptor is a G-protein coupled receptor.
26. (Currently Amended) The method of claim 1 ~~23~~, wherein the receptor is an opioid receptor.
27. (Currently Amended) The method of claim 1 ~~23~~, wherein the receptor is an opioid receptor selected from the group consisting of d,  $\mu$  and  $\kappa$ .
28. (Currently Amended) The method of claim 1 ~~23~~, wherein the hydrophilic moiety is selected from the group consisting of sugar and PEG<sub>1-7</sub>.
29. (Currently Amended) The method of claim 1 ~~23~~, wherein the hydrophilic moiety is selected from the group consisting of fatty acid, alkyl 1-26, cholesterol and adamantane.
30. (Currently Amended) The method of claim 1 ~~23~~, wherein the therapeutic compound is a peptide having an added N-terminal residue selected from the group consisting of proline and alanine.

31. (Currently Amended) The method of claim 1 ~~23~~, wherein the therapeutic compound is a peptide or protein.

32. (Currently Amended) The method of claim 1 ~~23~~, wherein the therapeutic compound is ~~a peptide and the peptide~~ is selected from the group consisting of: enkephalin, adrenocorticotrophic hormone, adenosine deaminase, ribonuclease, alkaline phosphatase, angiotensin, antibodies, arginase, arginine deaminase, asparaginase, caerulein, calcitonin, chemotrypsin, cholecystokinin, clotting factors, dynorphins, endorphins, enkephalins, erythropoietin, gastrin-releasing peptide, glucagon, hemoglobin, hypothalamic releasing factors, interferon, katacalcin, motilin, neuropeptide Y, neurotensin, non-naturally occurring opioids, oxytocin, papain, parathyroid hormone, prolactin, soluble CD-4, somatomedin, somatostatin, somatotropin, superoxide dismutase, thyroid stimulating hormone, tissue plasminogen activator, trypsin, vasopressin, and analogues and active fragments of ~~such peptides~~ any of the foregoing.

33. (Currently Amended) The method of claim 1 ~~23~~, wherein the ~~amphiphilic~~ oligomer is selected from the group of:



wherein  $n=3$  to 25 and  $m=1$  to 6;



wherein  $n=3$  to 25 and  $m=1$  to 7;




wherein  $n=3$  to 25,  $m=1$  to 7 and  $X=\text{O}$  or  $\text{N}$ ;




wherein  $m=0$  to 5 and  $\text{R}=\text{cholesterol}$  or  $\text{adamantane}$ ;



wherein  $m=0$  to 5;



wherein  $m=0$  to 7; and



wherein  $m=1$  to 7 and  $X=\text{N}$  or  $\text{O}$ .

34. (Currently Amended) The method of claim + 23, wherein the hydrophilic moiety is coupled to the hydrophobic moiety by a ~~hydrolysable~~ hydrolyzable bond.


35. (Currently Amended) The method of claim + 23, wherein the hydrophilic moiety is coupled to the hydrophobic moiety by a non-hydrolyzable bond.

Claims 36-63 are cancelled.

64. (Currently Amended) The method of claim + 23, wherein the therapeutic compound is an opioid receptor agonist, antagonist or partial agonist/partial antagonist.

65. (Currently Amended) The method of claim + 23, wherein the therapeutic compound is an enkephalin.

66. (New) The method of claim 23, wherein the conjugate comprises an amphiphilic oligomer having a formula:



wherein  $n=3$  to 25 and  $m=1$  to 6.

67. (New) The method of claim 23, wherein the conjugate comprises an amphiphilic oligomer having a formula:



wherein  $n=3$  to 25 and  $m=1$  to 7;

68. (New) The method of claim 23, wherein the conjugate comprises an amphiphilic oligomer having a formula:



wherein  $n=3$  to 25,  $m=1$  to 7 and  $X=\text{O}$  or  $\text{N}$ ;

69. (New) The method of claim 23, wherein the conjugate comprises an amphiphilic oligomer having a formula:




wherein  $m=0$  to 5 and  $\text{R}=\text{cholesterol}$  or  $\text{adamantane}$ ;

70. (New) The method of claim 23, wherein the conjugate comprises an amphiphilic oligomer having a formula:




wherein  $m=0$  to 5;

71. (New) The method of claim 23, wherein the conjugate comprises an amphiphilic oligomer having a formula:



wherein  $m=0$  to 7; and

72. (New) The method of claim 23, wherein the conjugate comprises an amphiphilic oligomer having a formula:



wherein  $m=1$  to 7 and  $X=N$  or  $O$ .

- 73. (New) The method of claim 23, wherein the conjugate is administered to the subject parenterally.
- 74. (New) The method of claim 23, wherein the conjugate is administered to the subject orally.
- 75. (New) The method of claim 23, wherein the activation of the receptor induces analgesia in the subject.
- 76. (New) The method of claim 34, wherein the activation of the receptor induces analgesia in the subject.
- 77. (New) The method of claim 35, wherein the activation of the receptor induces analgesia in the subject.
- 78. (New) The method of claim 73, wherein the activation of the receptor induces analgesia in the subject.
- 79. (New) The method of claim 74, wherein the activation of the receptor induces analgesia in the subject.